Ogivri

Ogivri Drug Interactions

trastuzumab

Manufacturer:

Biocon

Distributor:

DKSH

Marketer:

Meda Pharma
Full Prescribing Info
Drug Interactions
Patients who receive anthracycline after stopping trastuzumab products may be at increased risk of cardiac dysfunction because of trastuzumab's long washout period based on population PK analysis [see Pharmacology: Pharmacokinetics under Actions]. If possible, physicians should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab products. If anthracyclines are used, the patient's cardiac function should be monitored carefully.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in